表紙
市場調査レポート

世界の弧発性自己免疫疾患の市場(2017年まで)

Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market

発行 GBI Research 商品コード 224310
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
世界の弧発性自己免疫疾患の市場(2017年まで) Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
出版日: 2011年11月22日 ページ情報: 英文 88 Pages
概要

当レポートでは、弧発性自己免疫疾患(Orphan Autoimmune Disorders)に関する研究開発の世界市場について分析し、全体的な市場の構造・動向、代表的疾患(ITP、重症筋無力症、ALS)の治療環境、臨床研究の進展のパイプライン分析、主要企業のプロファイル、企業間の資本取引・提携などといった情報を取りまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 当レポートの構成

第3章 市場の特徴

  • 市場予測
    • 収益
    • 弧発性疾患(Orphan Diseases)の市場シェア
    • ジェネリック/オフラベル薬品の市場シェア
  • 弧発性自己免疫疾患治療の世界市場の促進・抑制要因
    • 市場促進要因
    • 市場抑制要因

第4章 各地域の市場動向

  • 地域別の収益分析
  • 米国
  • 欧州の上位5カ国
  • 日本

第5章 治療環境

  • 世界のITP(特発性血小板減少性紫斑病)治療市場の予測
    • 疾病の概要
    • 収益
    • ジェネリック薬品のシェア
    • 国別の収益分析
    • 年間治療費
    • 治療法の利用パターン
    • 主な市販製品
  • ITP治療市場の促進・抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の重症筋無力症の治療市場の予測
    • 疾病の概要
    • 収益
    • ジェネリック薬品のシェア
    • 国別の収益分析
    • 年間治療費
    • 治療法の利用パターン
    • 主な市販製品
  • 重症筋無力症の治療市場の促進・抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のALS(筋萎縮性側索硬化症)治療市場の予測
    • 疾病の概要
    • 収益
    • 国別の収益分析
    • 年間治療費
    • 治療法の利用パターン
    • 主な市販製品
  • ALS治療市場の促進・抑制要因
    • 市場促進要因
    • 市場抑制要因

第6章 パイプライン分析

  • 研究開発パイプライン:フェーズ別
  • 研究開発パイプライン:適応症別
  • ITP(特発性血小板減少性紫斑病):研究開発パイプライン
    • 概要
    • 臨床開発フェーズ別のパイプライン
  • 重症筋無力症:研究開発パイプライン
    • 概要
    • 臨床開発フェーズ別のパイプライン
  • ALS(筋萎縮性側索硬化症):研究開発パイプライン
    • 概要
    • 臨床開発フェーズ別のパイプライン
  • 臨床開発中の有望な薬剤
    • Venoglobulin-IH
    • Gammaplex
    • IGIV3I Grifols
    • Olesoxime (TRO19622)

第7章 企業プロファイル

  • Amgen Inc
    • 企業概要
    • 市販製品
    • SWOT分析
  • GlaxoSmithKline
    • 企業概要
    • 市販製品
    • SWOT分析
  • CSL Behring LLC
    • 企業概要
    • 市販製品
    • SWOT分析
  • 田辺三菱製薬
    • 企業概要
    • 研究開発パイプライン
    • SWOT分析
  • Biogen Idec
    • 企業概要
    • 研究開発パイプライン
    • SWOT分析

第8章 戦略的統合

  • 概要
  • 年度別分類
  • 適応症別分類
  • 地域別分類
  • 取引が区別分類
  • 主な企業合併・買収(M&A)
  • 主なライセンス契約
  • 主な共同開発合意

第9章 付録

図表一覧

目次

Summary

GBI Research's report, “Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market” provides in-depth analysis of the drivers and barriers that affect the global orphan autoimmune disorders. The report analyzes the markets for orphan autoimmune disorders therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the leading therapeutic segments. The report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the orphan autoimmune disorders market will show steady growth during the period 2010-2017. This growth will primarily be driven by the growth of the Idiopathic Thrombocytopenic Purpura (ITP) market, which has shown tremendous growth in terms of revenue between 2008 and 2010. Moreover, other key markets, such as myasthenia gravis and amyotrophic lateral sclerosis (ALS), will continue to grow steadily in the presence of very few molecules in the late stage of the product pipeline. The global orphan autoimmune disorders market is a niche market characterized by stiff competition from generics and off-label drugs and very few licensing agreements, co-development and M&A deals.

Scope

  • Annualized market data for the orphan autoimmune disorders therapeutics market from 2002 to 2010, and forecast to 2017.
  • Analysis of the leading therapeutic segments. These include ITP, myasthenia gravis and ALS.
  • Analysis of the orphan autoimmune disorders therapeutic markets in the leading geographies of the world, which include the US, top five countries of Europe and Japan.
  • Market characterization of the orphan autoimmune disorders (ITP, myasthenia gravis and ALS) market including market size, revenue analysis by top seven geographies, generic share, annual cost of therapy, and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of the pipeline molecules in various phases of drug development.
  • Competitive benchmarking of the leading companies. The key companies studied in this report are Amgen Inc., GlaxoSmithKline plc, CSL Behring LLC., Mitsubishi Tanabe Pharma Corporation and Biogen Idec.
  • Key M&A activities and licensing agreements that have taken place between 2004 and 2011 in the global orphan autoimmune disorders therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of the leading companies.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market”. It provides in-depth analysis of the drivers and barriers that affect the global orphan autoimmune disorders therapeutics market. The report analyzes the markets for orphan autoimmune disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographies as well as the leading therapeutic segments (ITP, myasthenia gravis and ALS). Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The Global Orphan Autoimmune Disorder Therapeutics Market Will Grow Steadily with Very Few Promising Molecules in the Pipeline

The orphan autoimmune disorder therapeutics market is one of the steadily growing markets in autoimmune therapeutics and is expected to show a significant growth in forecast period. The ITP and ALS market are the leading contributors to the global orphan autoimmune disorder therapeutics market in 2010. Moreover, the market for myasthenia gravis has shown a steady growth in terms of revenue and is expected to grow at a greater pace in the future.

The ITP market has witnessed a significant growth between 2008 and 2010 due to the launch of two novel second-line therapies, namely Nplate (romiplostim) and Promacta (eltrombopag), which stimulate platelet production in adults with chronic ITP. The ALS market has also shown a steady growth in terms of revenue in the presence of Rilutek, which is the only FDA approved drug for this indication. The myasthenia gravis market is dominated by generics and over-the-counter (OTC) drugs. However the approval of Prograf (tacrolimus hydrate) in Japan (October 2009) and the future launch of Venoglobulin-IH, a human immunoglobulin therapy is expected to boost the myasthenia gravis market in the forecasted period.

The Idiopathic Thrombocytopenic Purpura (ITP) Market is the Major Contributor to the Orphan Autoimmune Disorders Therapeutics Market

The ITP market has shown significant growth between 2008 and 2010 as two new drugs (thrombopoietins), namely Nplate and Promacta, were launched. Moreover, these drugs have shown a substantial growth in their revenue, which boosted the ITP market during this period (2008-2010). In addition, three immunoglobulin products (Rhophylac, Carimune and Privigen) of CSL Behring were launched with ITP as their extended indication. With long-term patent protection and exclusivity of Nplate and Promacta and existing immunoglobulin therapies, the global ITP market is anticipated to grow at a steady pace during the forecast period.

Low Prevalence Rates of Orphan Autoimmune Disorders Affect the Market Size and Growth

Orphan autoimmune disorders fall into the "rare diseases" category, which consists of indications with very low prevalence and incidence. According to one estimate, the average prevalence of ITP is just 9.5 to 20 per 100,000 people. The incidence of ITP in US adults is approximately 66 cases per 1,000,000 per year. On the other hand, the prevalence of myasthenia gravis in the US is estimated to be 14 to 20 per 100,000 people. According to ALS association data, around 30,000 Americans may currently be affected by ALS. The above statistics indicate that these orphan autoimmune disorders have very low prevalence rates and diseased populations, which has a great impact on their market size in terms of revenue.

Stiff Competition from Generics and Off-Label Products is Restraining the Growth of the Orphan Autoimmune Disorders Therapeutics Market

The global orphan autoimmune disorder therapeutics market faces tough competition from generics and off-label drugs. Myasthenia gravis, an orphan autoimmune disorder is a very small market in terms of revenue, where generic and off-label drugs together accounted for 100% of the market in 2010. Mestinon, a branded anticholinesterase inhibitor went off patent in 2003 in the US. Though Venoglobulin-IH is anticipated to launch in the forecast period, it would not have much impact on the generic share as it is estimated that the generic share will be declining by at a slow rate to reach approximately 74% by 2017.

In ITP and ALS markets 'branded drugs' take a significant market share. However the late-stage R&D pipelines for orphan autoimmune disorders principally comprises immunoglobulin therapies, a few corticosteroids and immunosuppressants. All these factors, coupled with lack of novel molecules in the pipeline, could be a major restraint to the market.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Orphan Autoimmune Disorders to 2017 - Introduction

  • 2.1. Overview
  • 2.2. GBI Research Report Guidance

3. Orphan Autoimmune Disorders to 2017 - Market Characterization

  • 3.1. Market Forecasts
    • 3.1.1. Revenue
    • 3.1.2. Market Share of Orphan Diseases
    • 3.1.3. Generic/Off-Label Share
  • 3.2. Drivers and Restraints for the Global Orphan Autoimmune Disorders Therapeutics Market
    • 3.2.1. Market Drivers
    • 3.2.2. Market Restraints

4. Orphan Autoimmune Disorders to 2017 - Geographical Landscape

  • 4.1. Revenue Analysis by Geography
  • 4.2. The US
    • 4.2.1. Revenue
  • 4.3. Top Five Countries of Europe
    • 4.3.1. Revenue
  • 4.4. Japan
    • 4.4.1. Revenue

5. Orphan Autoimmune Disorders to 2017 - Therapeutic Landscape

  • 5.1. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecasts
    • 5.1.1. Disease Overview
    • 5.1.2. Revenue
    • 5.1.3. Generic Share
    • 5.1.4. Revenue Analysis by Country
    • 5.1.5. Annual Cost of Treatment
    • 5.1.6. Treatment Usage Patterns
    • 5.1.7. Major Marketed Products
  • 5.2. Drivers and Restraints of the ITP Therapeutics Market
    • 5.2.1. Market Drivers
    • 5.2.2. Market Restraints
  • 5.3. Global Myasthenia Gravis Therapeutics Market Forecasts
    • 5.3.1. Disease Overview
    • 5.3.2. Revenue
    • 5.3.3. Generic Share
    • 5.3.4. Revenue Analysis by Country
    • 5.3.5. Annual Cost of Treatment
    • 5.3.6. Treatment Usage Patterns
    • 5.3.7. Major Marketed Products
  • 5.4. Drivers and Restraints of the Myasthenia Gravis Therapeutics Market
    • 5.4.1. Market Drivers
    • 5.4.2. Market Restraints
  • 5.5. Global Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market Forecasts
    • 5.5.1. Disease Overview
    • 5.5.2. Revenue
    • 5.5.3. Revenue Analysis by Country
    • 5.5.4. Annual Cost of Treatment
    • 5.5.5. Treatment Usage Patterns
    • 5.5.6. Major Marketed Products
  • 5.6. Drivers and Restraints of the ALS Therapeutics Market
    • 5.6.1. Market Drivers
    • 5.6.2. Market Restraints

6. Orphan Autoimmune Disorders to 2017 - Pipeline Analysis

  • 6.1. Research and Development Pipeline by Phase
  • 6.2. Research and Development Pipeline by Indication
  • 6.3. Idiopathic Thrombocytopenic Purpura (ITP): Research and Development Pipeline
    • 6.3.1. Overview
    • 6.3.2. Pipeline by Clinical Phases of Development
  • 6.4. Myasthenia Gravis: Research and Development Pipeline
    • 6.4.1. Overview
    • 6.4.2. Pipeline by Clinical Phases of Development
  • 6.5. Amyotrophic Lateral Sclerosis (ALS): Research and Development Pipeline
    • 6.5.1. Overview
    • 6.5.2. Pipeline by Clinical Phases of Development
  • 6.6. Promising Drugs under Clinical Development for Orphan Autoimmune Disorders
    • 6.6.1. Venoglobulin-IH
    • 6.6.2. Gammaplex
    • 6.6.3. IGIV3I Grifols
    • 6.6.4. Olesoxime (TRO19622)

7. Orphan Autoimmune Disorders to 2017 - Competitive Profiling

  • 7.1. Amgen Inc.
    • 7.1.1. Company Overview
    • 7.1.2. Marketed Products for Orphan Autoimmune Disorders
    • 7.1.3. SWOT Analysis
  • 7.2. GlaxoSmithKline
    • 7.2.1. Company Overview
    • 7.2.2. Marketed Products for Orphan Autoimmune Disorders
    • 7.2.3. SWOT Analysis
  • 7.3. CSL Behring LLC
    • 7.3.1. Company Overview
    • 7.3.2. Marketed Products for Orphan Autoimmune Disorders
    • 7.3.3. SWOT Analysis
  • 7.4. Mitsubishi Tanabe Pharma Corporation
    • 7.4.1. Company Overview
    • 7.4.2. Orphan Autoimmune Disorders- R&D Pipeline
    • 7.4.3. SWOT Analysis
  • 7.5. Biogen Idec.
    • 7.5.1. Company Overview
    • 7.5.2. Orphan Autoimmune Disorders- R&D Pipeline
    • 7.5.3. SWOT Analysis

8. Orphan Autoimmune Disorders to 2017 - Strategic Consolidations

  • 8.1. Overview
  • 8.2. Segmentation by Year
  • 8.3. Segmentation by Indication
  • 8.4. Segmentation by Geography
  • 8.5. Segmentation by Deal Value
  • 8.6. Major Mergers and Acquisitions (M&A)
  • 8.7. Major Licensing Agreements
  • 8.8. Major Co-Development Deals

9. Orphan Autoimmune Disorders to 2017 - Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
    • 9.3.3. Primary Research
    • 9.3.4. Therapeutic Landscape
    • 9.3.5. Epidemiology-based Forecasting
    • 9.3.6. Market Size by Geography
    • 9.3.7. Geographical Landscape
    • 9.3.8. Pipeline Analysis
    • 9.3.9. Competitive Landscape
    • 9.3.10. Expert Panel Validation
  • 9.4. Contact Us
  • 9.5. Disclaimer
  • 9.6. Sources

List of Tables

  • Table 1: Orphan Autoimmune Disorders, Global, Revenue ($m), 2002- 2010
  • Table 2: Orphan Autoimmune Disorders, Global, Revenue ($m), 2010- 2017
  • Table 3: Orphan Autoimmune Disorders, Market Share of Orphan Diseases, (%), 2010
  • Table 4: Orphan Autoimmune Disorders, Global, Revenue Analysis by Geography ($m), 2002-2010
  • Table 5: Orphan Autoimmune Disorders, Global, Revenue Analysis by Geography ($m), 2010-2017
  • Table 6: Orphan Autoimmune Disorders, The US, Revenue ($m), 2002-2010
  • Table 7: Orphan Autoimmune Disorders, The US, Revenue ($m), 2010-2017
  • Table 8: Orphan Autoimmune Disorders, Top Five Countries of Europe, Revenue ($m), 2002-2010
  • Table 9: Orphan Autoimmune Disorders, Top Five Countries of Europe, Revenue ($m), 2010-2017
  • Table 10: Orphan Autoimmune Disorders, Japan, Revenue ($m), 2002-2010
  • Table 11: Orphan Autoimmune Disorders, Japan, Revenue ($m), 2010-2017
  • Table 12: ITP Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 13: ITP Therapeutics Market, Global, Revenue ($m), 2010-2017
  • Table 14: ITP Therapeutics Market, Global, Revenue Analysis by Country ($m), 2002-2010
  • Table 15: ITP Therapeutics Market, Global, Revenue Analysis by Country ($m), 2010-2017
  • Table 16: ITP Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 17: ITP Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 18: ITP Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002-2010
  • Table 19: ITP Therapeutics Market, Global, Treatment Usage Patterns ('000), 2010-2017
  • Table 20: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2002-2010
  • Table 21: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2010-2017
  • Table 22: Myasthenia Gravis Therapeutics Market, Global, Revenue Analysis by Country ($m), 2002-2010
  • Table 23: Myasthenia Gravis Therapeutics Market, Global, Revenue Analysis by Country ($m), 2010-2017
  • Table 24: Myasthenia Gravis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 25: Myasthenia Gravis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
  • Table 26: Myasthenia Gravis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002-2010
  • Table 27: Myasthenia Gravis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2010-2017
  • Table 28: ALS Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2010
  • Table 29: ALS Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017
  • Table 30: ALS Therapeutics Market, Global, Revenue by Country ($m), 2002-2010
  • Table 31: ALS Therapeutics Market, Global, Revenue by Country ($m), 2010-2017
  • Table 32: ALS Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
  • Table 33: ALS Therapeutics Market, Annual Cost of Treatment, Global, ($), 2010-2017
  • Table 34: ALS Therapeutics Market, Global Treatment Usage Pattern (hundred), 2002-2010
  • Table 35: ALS Therapeutics Market, Global Treatment Usage Pattern (hundred), 2010-2017
  • Table 36: Orphan Autoimmune Disorders, Global, Pipeline Molecules by Phase, (%), 2011
  • Table 37: Orphan Autoimmune Disorders, Global, Pipeline Molecules by Indication, (%), 2011
  • Table 38: ITP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011
  • Table 39: ITP Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011
  • Table 40: ITP Therapeutics Market, Global, Phase I Pipeline Molecules, 2011
  • Table 41: ITP Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
  • Table 42: ITP Therapeutics Market, Global, Phase III Pipeline Molecules, 2011
  • Table 43: Myasthenia Gravis Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011
  • Table 44: Myasthenia Gravis Therapeutics Market, Global, IND Filed Pipeline Molecules, 2011
  • Table 45: Myasthenia Gravis Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
  • Table 46: Myasthenia Gravis Therapeutics Market, Global, Phase III/NDA Filed Pipeline Molecules, 2011
  • Table 47: ALS Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011
  • Table 48: ALS Therapeutics Market, Global, Discovery Pipeline Molecules, 2011
  • Table 49: ALS Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011
  • Table 50: ALS Therapeutics Market, Global, Phase I Pipeline Molecules, 2011
  • Table 51: ALS Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
  • Table 52: ALS Therapeutics Market, Global, Phase III Pipeline Molecules, 2011
  • Table 53: Orphan Autoimmune Disorder Therapeutics Market, Mitsubishi Tanabe, Pipeline Products for Orphan Autoimmune Disorders, 2011
  • Table 54: Orphan Autoimmune Disorder Therapeutics Market, Biogen Idec, Pipeline Products for Orphan Autoimmune Disorders, 2011
  • Table 55: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Type, (%), 2004-2011
  • Table 56: Orphan Autoimmune Disorder Therapeutics Market, Global, Number of Deals by Year, 2004-2011
  • Table 57: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Indication, (%), 2004-2011
  • Table 58: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Geography, (%), 2004-2011
  • Table 59: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Value, (%), 2004-2011
  • Table 60: Orphan Autoimmune Disorder Therapeutics Market, Global, Major M&A Deals, 2007-2011
  • Table 61: Orphan Autoimmune Disorder Therapeutics Market, Global, Major Licensing Agreements, 2007-2011
  • Table 62: Orphan Autoimmune Disorder Therapeutics Market, Global, Major Co-Development Deals, 2006-2011

List of Figures

  • Figure 1: Orphan Autoimmune Disorders, Global, Revenue ($m), 2002- 2017
  • Figure 2: Orphan Autoimmune Disorders, Market Share of Orphan Diseases (%), 2010
  • Figure 3: Orphan Autoimmune Disorders, Global, Generic/Off-Label Revenue Share (%), 2010
  • Figure 4: Orphan Autoimmune Disorders, Global, Revenue Analysis by Geography ($m), 2002-2017
  • Figure 5: Orphan Autoimmune Disorders, The US, Revenue ($m), 2002-2017
  • Figure 6: Orphan Autoimmune Disorders, Top Five Countries of Europe, Revenue ($m), 2002-2017
  • Figure 7: Orphan Autoimmune Disorders, Japan, Revenue ($m), 2002-2017
  • Figure 8: ITP Therapeutics Market, Global, Revenue ($m), 2002-2017
  • Figure 9: ITP Therapeutics Market, Global, Generic Share(%), 2010, 2017
  • Figure 10: ITP Therapeutics Market, Global, Revenue Analysis by Country ($m), 2002-2017
  • Figure 11: ITP Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 12: ITP Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002-2017
  • Figure 13: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2002-2017
  • Figure 14: Myasthenia Gravis Therapeutics Market, Global, Generic Share (%), 2010, 2017
  • Figure 15: Myasthenia Gravis Therapeutics Market, Global, Revenue Analysis by Country ($m), 2002-2017
  • Figure 16: Myasthenia Gravis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 17: Myasthenia Gravis Therapeutics Market, Global, Treatment Usage Patterns ('000), 2002-2017
  • Figure 18: ALS Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017
  • Figure 19: ALS Therapeutics Market, Global, Revenue by Country ($m), 2002-2017
  • Figure 20: ALS Therapeutics Market, Global, Generic Share (%), 2010, 2017
  • Figure 21: ALS Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
  • Figure 22: ALS Therapeutics Market, Global Treatment Usage Pattern (hundred), 2002-2017
  • Figure 23: Orphan Autoimmune Disorders, Global, Pipeline Molecules by Phase, (%), 2011
  • Figure 24: Orphan Autoimmune Disorders, Global, Pipeline Molecules by Indication, (%), 2011
  • Figure 25: ITP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011
  • Figure 26: Myasthenia Gravis Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011
  • Figure 27: ALS Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011
  • Figure 28: Orphan Autoimmune Disorders, Amgen Inc, SWOT Analysis, 2011
  • Figure 29: Orphan Autoimmune Disorders, GlaxoSmithKline plc., SWOT Analysis, 2011
  • Figure 30: Orphan Autoimmune Disorders, CSL Behring LLC, SWOT Analysis, 2011
  • Figure 31: Orphan Autoimmune Disorders, Mitsubishi Tanabe Pharma Corporation, SWOT Analysis, 2011
  • Figure 32: Orphan Autoimmune Disorders, Biogen Idec, SWOT Analysis, 2011
  • Figure 33: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Type (%), 2004-2011
  • Figure 34: Orphan Autoimmune Disorder Therapeutics Market, Global, Number of Deals by Year (%), 2004-2011
  • Figure 35: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Indication, (%), 2004-2011
  • Figure 36: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Geography, (%), 2004-2011
  • Figure 37: Orphan Autoimmune Disorder Therapeutics Market, Global, Deals by Value (%), 2004-2011
  • Figure 38: GBI Research Market Forecasting Model
Back to Top